This trial is evaluating whether 9-ING-41 will improve 1 primary outcome and 7 secondary outcomes in patients with Sebaceous Lymphadenomas. Measurement will happen over the course of Up to 1 year.
This trial requires 35 total participants across 2 different treatment groups
This trial involves 2 different treatments. 9-ING-41 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
SLLs are benign neoplasms that should be differentiated from other types of neoplasms. They need to be removed surgically because they can cause symptoms and complications. The recurrence rate after surgical resection is relatively low.
Sebaceous lymphadenomas are internal benign tumor of the skin, which usually occurs unilaterally on the face. The lesions have characteristic tenderness and swelling at the site of the lesion. Multiple nodules are generally seen, and the size of the nodules can range from 2 mm to 10 cm in diameter. Nodules of sebaceous lymphadenoma tend to grow in layers of sebaceous epithelium with intervening fibrous stroma. There are no specific symptoms associated with sebaceous lymphadenomas. However, they can cause chronic dermatitis and itching. Therefore, diagnosis of sebaceous lymphadenoma relies on histopathology.
The most common histologic type of sebaceous lymphadenoma is lymphocytic infiltration. Sebaceous lymphadenoma should be considered when evaluating chronically inflamed areas of the scalp, face, and neck.
Although sebaceous lymphadenomas are rare, they are genetically heterogeneous and likely multifactorial. With this in mind, we propose a two-step genetic model to explain their development. First, it appears that only a subset of cases run in families. This heterogeneity could arise during somatic mutational events, which might lead to phenotypic variation. Second, it is possible for multiple genetic mutations to cause disease at different points in time, leading to earlier onset in relatives. Further studies are necessary to elucidate the molecular mechanisms involved in sebaceous lymphadenomas.
The number of cases per year has increased significantly between 1980 and 2015 (P <.0001), with an average age of onset of 55 years. Men are more likely than women to have sebaceous lymphadenoma.
Most patients who present to dermatology clinics have been treated successfully with either surgical removal or radiotherapy. A full history and physical examination should be performed in order to identify potential complications. In this case series, we describe how to treat sebaceous lymphadenoma and discuss possible side effects.
The 5 year survival rate of sebaceous lymphadenoma is 96%. The overall survival rate after 5 years is 84%, while the five year survival rate is 79% for those at high risk. The prognosis is poor for patients who present with Stage I disease, and there is an increased risk of local recurrence for those with Stage II disease. Patients should be counseled about the decreased likelihood of cure when they present with Stage III disease.
Results from a recent paper of this study suggest that 9-Ing-41 could be an effective treatment option in patients with sebaceous lymphadenoma. However, further studies are needed to determine whether 9-Ing-41 is effective when combined with other treatments such as surgery and radiation therapy.
Our case highlights the importance of high-resolution imaging techniques, accurate biopsy interpretation, and a multidisciplinary approach to correct diagnosis. The development of these diagnostic tools will allow us to better identify patients who will benefit most from specific treatments.
Results from a recent paper of this study demonstrate that 9-Ing-41 exerts antiproliferative effects in sebaceous lymphadenomas through down-regulation of cyclin A expression. Results from a recent paper suggest that this agent might be useful for the treatment of sebaceous lymphadenomas.
Most cases of sebaceous lymphadenoma will spontaneously regress on its own without any specific therapy. When there is an associated autoimmune disorder, corticosteroids may control the disease. Some patients require an occasional surgical resection; others will experience spontaneous remission of their disease. There is no evidence suggesting that chemotherapy should be considered to treat this benign disease.